Sarepta Therapeutics (SRPT) Now Covered by Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Friday. The firm issued a buy rating and a $75.00 target price on the biotechnology company’s stock.
SRPT has been the subject of a number of other research reports. Goldman Sachs Group reiterated a buy rating and issued a $71.00 price target on shares of Sarepta Therapeutics in a report on Friday, October 6th. ValuEngine lowered Sarepta Therapeutics from a hold rating to a sell rating in a report on Monday, October 2nd. Oppenheimer reiterated a buy rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. SunTrust Banks restated a buy rating and set a $56.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Finally, Robert W. Baird restated a buy rating and set a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $64.14.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down $0.42 during midday trading on Friday, hitting $55.25. The company had a trading volume of 1,713,742 shares, compared to its average volume of 1,778,143. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $57.57.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the previous year, the business earned ($0.95) earnings per share. analysts anticipate that Sarepta Therapeutics will post -3.11 EPS for the current year.
In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 38,138 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the transaction, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Shamim Ruff sold 11,500 shares of the company’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its position in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 2,474 shares during the period. Edge Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $175,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $204,000. 82.02% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.